2022 年第 10 次第三人體試驗委員會會議記錄

2022 year 10th-C IRB Meeting Minutes

- 一、日 期 Date(YY/MM/DD): 2022 年 10 月 27 日 (星期四)
- 二、時 間 Time: 12:00-13:32
- 三、地 點 Location: 蘭醫師大樓 B1 尊榮 B 廳 / Webex
- 四、主 席 Chairperson:

顏旭亨(院內、醫療、醫師、男性)

Yen, Hsu-Heng (Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)

出席人員 Attendant: (職稱略 omit title)

- 曹紹倫 (院內、醫療、醫師、男性)
 Tsao, Shao-Lun (Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)
- 高峻凱(院内、醫療、醫師、男性) Kao, Jun-Kai(Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)
- 倪渟淵(院內、醫療、醫師、女性)
 Ni, Ting-Yuan (Affiliation with Institution, Medical Personnel (Scientific member), doctor, female)
- 蔡忠融(院外、醫療、公衛/統計、男性) Tsai, Chung-Jung(non-Affiliation with Institution, Medical Personnel (Scientific member), Epidemiology/ Statistics, male)
- 洪婉純(院內、非醫療、社工、女性)【熟稔易受傷害族群-員工:屬有風險、非屬於具有風險及防疫核心人員、社工師】

 Hung Wan Chun (Affiliation with Institution Nonmedical Personnel (non Scientific
 - Hung, Wan-Chun (Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Social Worker, female)
- 陳明鋒(院內、非醫療、法律專業、男性) 【熟稔易受傷害族群-員工:屬有風險、 非屬於具有風險及防疫核心人員,法律專家】
 - Chen, Ming-Fong (Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Law, male)
- 蔡佩凌(院外、醫療、藥師、女性) Tsai, Pei-Ling(non-Affiliation with Institution, Medical Personnel (Scientific member), Pharmacist, female)
- 龔心怡(院外、非醫療、社會公正人士、女性)
 Kung, Hsin-Yi (non-Affiliation with Institution, Nonmedical Personnel (Scientific member), Member of society, female)

■ 吳姿慧(院外、非醫療、家庭主婦、女性)

Wu, Tzu-Hui (non-Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Member of society, female)

	人數	備註 Remark	
	Persons		
醫療	6	醫師(4)、藥師(1)、統計(1)	
Medical		Doctor (4), Pharmacist (1), Statistics (1)	
Personnel			
非醫療	4	社工(1)、法律(1)、社會公正人士(2)	
Nonmedical		Social Worker (1), Law (1), Member of society (2)	
Personnel			
科學	7	醫師(4)、藥師(1)、統計(1)、社會公正人士(1)	
Scientific		Doctor (4), Pharmacist (1), Statistics (1), Member of	
member		society (1)	
非科學	3	社工(1)、法律(1)、社會公正人士(1)	
non-Scientific		Social Worker (1), Law (1), Member of society (1)	
member			
男	5	院內(4)、院外(1)	
Male		Affiliation with Institution (4), non-Affiliation with	
		Institution (1)	
女	5	院内(2)、院外(3)	
Female		Affiliation with Institution (2), non-Affiliation with	
		Institution (3)	

備註:① 依據「人體研究法」第七條:審查會應置委員五人以上,包含法律專家及其他社會公正人士;研究機構以外人士應達五分之二以上;任一性別不得低於三分之一。審查會開會時,得邀請研究計畫相關領域專家,或研究對象所屬特定群體之代表列席陳述意見。

Remark: (According to Article 7 of Human Body Research Law, the review board shall comprise of at least 5 board members, including legal experts and other impartial citizens. More than two-fifths of the board members shall be persons not affiliated with the research institution and either of the genders shall not account for less than one-third of the board. Experts in the field related to the study protocol or representatives of the special population in the study shall be invited to attend review board meetings and voice their opinions.

② 依據「人體研究倫理審查委員會組織及運作管理辦法」第六條:審查 會召開一般程序審查會議時,其出席委員應包括機構外之非具生物醫 學科學背景委員一人以上。五人以上,不足七人之審查會,應有三分 之二以上之委員出席;七人以上之審查會,應有半數以上之委員出席,始得開會。出席委員均為單一性別時,不得進行會議。

② According to Article 6 of "The Organization and Operation of Human Research Ethics Review Board," attendees of the general board meetings shall include more than 1 board member who is not affiliated with the institution and who does not have biomedical background. For review boards of more than 5 members and less than 7 members, more than two-thirds of the members shall attend the meetings. For review boards of more than 7 members, the meeting shall only start if more than half of the members are present. If all the attendees are of the similar gender, the meeting shall not be conducted.

列席人員 Presenting staff: (職稱略 omit title)

- 黄淑萍 (IRB 秘書) Ng Sock Ping (IRB secretary)
- 葉正吉 (IRB 行政人員) Yeh, Cheng Chi (IRB staff)
- 林巧芸 (IRB 行政人員) Lin, Ciao Yun (IRB staff)
- 洪翠霞 (IRB 行政人員) Hung, Tsui-Hsia (IRB staff)
- 李欣儀 (IRB 行政人員) Li, Hsin-Yi (IRB staff)
- 請 假 Leave: (職稱略 omit title)
- 高小玲(院内、醫療、公衛/統計、女性) Kao, Hsiao-Ling(Affiliation with Institution, Medical Personnel (Scientific member), Member of society, female)
- 蕭玲玲(院外、非醫療、家庭主婦、女性) Hsiao, Ling-Ling(non-Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Member of society, female)

缺 席 Absence: (職稱略 omit title)

記 錄 Recorder: 洪翠霞 Hung, Tsui-Hsia (IRB staff)

五、會議內容 Meeting:

(一) 討論議案 (議案主題及決議) Discussion (theme and decision)

主題	計畫名稱	決議
編號: 221012 【新案】 主持人: 陳昶華	台灣中部地區某醫療機構其醫療從業人員新型 冠狀病毒(SARS-CoV-2)流行病學篩檢專案	修正後複審
編號:220603 【變更案第3次】	一個隨機、雙盲、安慰劑對照的第II期臨床試驗, 針對輕度至中度的帕金森失智症患者給予頭孢	核准

主持人: 巫錫霖	曲松(ceftriaxone)後的有效性與安全性	
工107人,四國和	面似(certificatione)及时有双压杂文主任	
編號:171010	一項第 3 期、多中心、雙盲、隨機分配、安慰	存查,同意試驗繼續進行
【不遵從事件】	劑對照試驗,在罹患先前未治療且帶有 IDH1 突	
202210-5	變之急性骨髓性白血病的 18 歲受試者中,探討	
主持人:賴冠銘	AG-120 併用 Azacitidine 療法	
編號:180712	一項針對分期 AJCC/UICC 第 8 版 II-IIIA 及	存查,同意試驗繼續進行
【不遵從事件】	IIIB (T>5cm N2) 完全切除 (R0) 之非小細胞肺	
202209-8	癌 (NSCLC) 成年受試者,評估 canakinumab 相	
主持人: 林聖皓	較於安慰劑做為輔助療法之療效及安全性的第	
	三期、多中心、隨機分配、雙盲、安慰劑對照試	
	驗	
編號:210505	一項在有腎功能逐漸喪失風險之 A 型免疫球蛋	存查,同意試驗繼續進行
【不遵從事件】	白 (IgA) 腎病變患者中探討 Atrasentan 的第 3	
202210-1	期、隨機分配、雙盲、安慰劑對照試驗(ALIGN	
主持人:楊郁	試驗)	

(二)已通過之初審案(簡易審查) Report the approved protocol by expedited review

				醫療主審	非醫療主審
序號	IRB 編號	計畫名稱	主持人	Medical	Non-Medical
No.	IRB No.	Protocol title	PI	primary	primary
				reviewer	reviewer
1	220822	探討護理人員知覺智慧醫療之有用性、易	王美玲	(略)	(略)
		用性與工作重塑、工作結果之關係	Mei-Ling	(N/A)	(N/A)
		An exploration of the relationships among	Wang		
		nurses' perceived usefulness, ease of use, job			
		crafting and work results for eHealth			
2	220911	將人工智慧應用於偵測胎兒腦部異常之超	謝聰哲	(略)	(略)
		音波影像	Hsieh	(N/A)	(N/A)
		Application of real-time artificial intelligence	TsungChe		
		(AI) on detection of fetal brain abnormality			
		image in standard reference plans of prenatal			
		ultrasound.			
3	220920	失智共照模式下神經精神症狀和抗精神病	張凱茗	(略)	(略)
		用藥與失智進展的關聯性	Jhang Kai	(N/A)	(N/A)
		Association of neuropsychiatric symptoms	Ming		
		and antipsychotic medication with dementia	_		
		progression in a dementia co-illumination			
		model			

(三)報告已核准之變更案(簡易審查) Report the approved amendment by expedited review

				醫療主審	非醫療主審
序號	IRB 編號	計畫名稱	主持人	Medical	Non-Medical
No.	IRB No.	Protocol title	PI	primary	primary
				reviewer	reviewer
1	210515	頭頸癌臨床資訊結合AI預測疾病發展及預	謝明妤	(略)	(略)
	【第1次】	後	Ming-Yu	(N/A)	(N/A)
		Utilizing Artificial Intelligence for Head and	Hsiesh		
		Neck Cancer Outcomes Prediction From			
		Clinical Data			
2	220603	一個隨機、雙盲、安慰劑對照的第II期臨床	巫錫霖	(略)	(略)
	【第2次】	試驗,針對輕度至中度的帕金森失智症患	Wu Shey	(N/A)	(N/A)
		者給予頭孢曲松(ceftriaxone)後的有效性與	Lin		
		安全性			
		A randomized, double blinded,			
		placebo-controlled Phase II study to assess			
		the efficacy and safety of ceftriaxone in			
		patients with mild to moderate Parkinson's			
		disease dementia			

(四)報告已核准之期中報告(簡易審查) Report the approved interim report by expedited review

				醫療主審	非醫療主審
序號	IRB 編號	計畫名稱	主持人	Medical	Non-Medical
No.	IRB No.	Protocol title	PI	primary	primary
				reviewer	reviewer
1	150812	乳頭乳暈保留乳房全切除手術應用於台灣	賴鴻文	(略)	(略)
	【第7次】	婦女乳癌的回溯性分析及前瞻性研究	Hung Wen	(N/A)	(N/A)
		Nipple sparing mastectomy in the treatment	Lai		
		of Taiwanese women with breast			
		cancer- Retrospective analysis and			
		prospective study.			
2	191220	建立週邊血液偵測 EB 病毒技術協助國衛	林進清	(略)	(略)
	【第3次】	院鼻咽癌多中心臨床計畫執行	Jin-Chin Lin	(N/A)	(N/A)
		Establish Epstein-Barr virus quantification			
		assay from the peripheral blood and assist the			
		the performance of National Health Research			
		Institute multi-center NPC studies			
3	211026	紅斑性狼瘡的自然疾病病程及長期預後之	田雅之	(略)	(略)
	【第1次】	研究	YaChih	(N/A)	(N/A)
		The long term prognosis and the nature	Tien		
		course of systemic lupus erythematosus			

(五)報告已存查之結案報告 Report the final report for reference

				醫療主審	非醫療主審
序號	IRB 編號	計畫名稱	主持人	Medical	Non-Medic
No.	IRB No.	Protocol title	PI	primary	al primary
				reviewer	reviewer
1	100915	一項第三期臨床試驗,在使用 lapatinib 合併 trastuzumab 與芳香環轉化?抑制劑 (AI)、或 trastuzumab 合併芳香環轉化?抑制劑 或 lapatinib 合併芳香環轉化?抑制劑作為第一或第二線療法,用於已接受過trastuzumab 及內分泌治療之停經後、荷爾蒙受體及 HER2 為陽性的轉移性乳癌(MBC) 受試者,比較其安全性及療效A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an	Shou-Tung	(略) (N/A)	(略) (N/A)
		aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received prior trastuzumab and endocrine therapies.			
2	200331	以高擬真模擬情境於臨床醫護人員進行臨床急救能力和醫療團隊資源管理之學習成效 Learning effectiveness of emergency and critical care capability and team resource management in medical and nursing staff with high-fidelity simulation.	李雅文 YA WEN LEE	(略) (N/A)	(略) (N/A)
3	211022	肝臟移植後病人生活品質之探討 Quality of life among patients after liver transplantation	蘇淑女 Shu Nu SU	(略) (N/A)	(略) (N/A)

(六)報告已存查之暫停報告 Report the terminated protocol(無 None)

(七)報告已存查之終止報告 Report the terminated protocol

序號 No.	IRB 編號 IRB No.	計畫名稱 Protocol title	主持人 PI	醫療主審 Medical primary reviewer	審查結果 Review result
1	181007	不動桿菌之適當治療效果; 一前瞻性觀察研究 Effect of appropriate therapy on patients infected by Acinetobacter spp.; a prospective, observational study.	劉元孟 Yuan-Meng Liu	(略) (N/A)	存查 File for reference

(八)報告已存查之撤案報告 Report the withdraw protocol(無 None)

(九)報告已核准之國衛院/ JIRB/ C-IRB/ NRPB Report the ratifiy protocol that was approved by NHRI/ JIRB/ C-IRB/ NRPB

		國衛院/ JIRB/ C-IRB/ NRPB					
序號	IRB 編號	編號	階段次數	主持人			
No.	IRB No.	NHRI/ JIRB/ C-IRB/ NRPB	Stage	PI			
		protocol No.					
		計畫名稱	Protocol title				
	171010	[CIRB] 106CIRB06098	變更案第17次初審	賴冠銘			
1				KuanMing Lai			
	一項第 3 期、多中心、雙盲、隨機分配、安慰劑對照試驗,在罹患先前未治療且帶有 IDH1 突						
	變之急性骨髓	5 性白血病的 18 歲受試者中,	深討 AG-120 併用 Azacitidi	ne 療法			
	A Phase 3, M	Multicenter, Double-Blind, Rand	lomized, Placebo-Controlled	Study of AG-120 in			
		with Azacitidine in Subjects ?1	8 Years of Age with previous	usly Untreated Acute			
	•	emia with an IDH1 Mutation					
2	190807	【CIRB】107CIRB10166	變更案第5次 初審	陳穆寬			
				MuKuan Chen			
		隨機分配、雙組、開放性標示					
		法)期間或之後治療失敗或疾病					
		護療法用於治療局部區域性復興					
		Randomized, Double-Arm,	-				
		therapy Versus Physician's Cl Recurrent Head and Neck Squam					
	_	or After at Least Two Lines of					
	Systemic Ther		in Therapy, or which at Leas	of the Line what be			
3	200510	[CIRB] 109CIRB03035	變更案第5次 初審	顏旭亨			
		(che) iosenesosos	· 交叉水剂 • 八 // // // // // // // // // // // // /	HsuHeng Yen			
	一項第 2b/3 其		L 環、平行分組、多中心,評估				
		性潰瘍性結腸炎患者之療效和		DC/13/3			
		Randomized, Double-blind, Place		Multicenter Protocol			
	to Evaluate th	e Efficacy and Safety of Guselk	rumab in Participants with M	oderately to Severely			
	Active Ulcerat	ive Colitis					
4	201006	【CIRB】109CIRB06111	變更案第6次 初審	林進清			
_				Jin-Chin Lin			
		隨機分配、雙盲、安慰劑對照					
	性化學放射療法用於局部晚期、無法手術切除的食道鱗狀細胞癌之患者(KUNLUN)						
	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-center International Study of						
	Durvalumab Given Concurrently with Definitive Chemoradiation Therapy in Patients with Locally						
		resectable Esophageal Squamous		44.11.11			
5	210105	【CIRB】109CIRB11210	變更案第6次 初審	杜思德			
	医医状型 人产	=====================================	巨型分布在中部	Tu shih te			
		毒試驗疫苗於 60 歲(含)以上年					
	-	ty, safety, reactogenicity and per		respiratory syncytial			
	virus (RSV) vaccine in adults aged 60 years and above.						

6		220624	【CIRB】111CIRB03053	變更案第2次 初審	邱南英		
	U				Nan-Ying Chiu		
		一項為期6週	1、雙盲、安慰劑對照、並額外	有 18 週盲性延伸期的試驗,	用以評估 Cariprazine		
		用於思覺失調症急性發作的療效與安全性					
		A 6-Week, I	Double-Blind, Placebo-Controlle	ed Study Evaluating the Eff	icacy and Safety of		
		Cariprazine in	n the Acute Exacerbation of Sc	chizophrenia, with an Addition	nal 18-Week Blinded		
		Extension Peri	iod				